PMID- 33944625
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220502
IS  - 1461-7285 (Electronic)
IS  - 0269-8811 (Linking)
VI  - 36
IP  - 3
DP  - 2022 Mar
TI  - Challenges in translational research: MDMA in the laboratory versus therapeutic 
      settings.
PG  - 252-257
LID - 10.1177/02698811211015221 [doi]
AB  - Despite substantial progress in the use of mind-altering drugs to treat 
      psychiatric disorders, the psychological processes through which these drugs 
      change mood or behavior are poorly understood. Controlled laboratory studies with 
      well-defined psychological constructs are valuable to understand how these drugs 
      manifest their therapeutic benefit. However, there are substantial methodological 
      differences between clinical studies investigating therapeutic outcome and 
      laboratory studies investigating the processes that might underlie the 
      therapeutic effects. Here, we examine some of these differences using the example 
      of 3,4-methylenedioxymethamphetamine (MDMA). We review differences in 
      expectancies, social and physical context, participant characteristics, 
      pharmacological factors, and outcome measures in studies with participants who do 
      or do not have psychiatric diagnoses. We describe the challenges and 
      opportunities in translating findings from laboratory studies to the clinic and 
      identify ways to bridge the gap between these approaches.
FAU - de Wit, Harriet
AU  - de Wit H
AUID- ORCID: 0000-0002-7211-8994
AD  - Department of Psychiatry and Behavioral Neuroscience, The University of Chicago, 
      Chicago, IL, USA.
FAU - Bershad, Anya K
AU  - Bershad AK
AD  - Semel Institute for Neuroscience and Human Behavior, University of California at 
      Los Angeles, CA, USA.
FAU - Grob, Charles
AU  - Grob C
AD  - The Lundquist Institute and Department of Psychiatry and Biobehavioral Sciences, 
      University of California at Los Angeles, CA, USA.
LA  - eng
GR  - R01 DA002812/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20210504
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Affect
MH  - Humans
MH  - *Mental Disorders/drug therapy
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/pharmacology/therapeutic use
MH  - Translational Research, Biomedical
OTO - NOTNLM
OT  - MDMA
OT  - Translational
OT  - mental disorders
OT  - research design
EDAT- 2021/05/05 06:00
MHDA- 2022/05/03 06:00
CRDT- 2021/05/04 12:19
PHST- 2021/05/05 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2021/05/04 12:19 [entrez]
AID - 10.1177/02698811211015221 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2022 Mar;36(3):252-257. doi: 10.1177/02698811211015221. Epub 
      2021 May 4.